What is Hemab Therapeutics Holdings, Inc. Common Stock (COAG)?

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of COAG?

The current price of COAG is $41.45. Prices are updated in real time on Stocks360.

What is COAG's price-to-earnings (PE) ratio?

COAG's trailing twelve-month PE ratio is -31.64, based on current price and earnings per share data available on Stocks360.

What is COAG's market capitalization?

COAG's market capitalization is $1,936,217,208.00, placing it in the small-cap tier.

Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$41.45

Market Cap

$1.94B

PE (TTM)

-31.64

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.85

Day Range

$39.38 – $42.85

52-wk Range

$23.00 – $55.42

Avg Volume

N/A

Volume

765.55K

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is a publicly traded company in the Healthcare sector. Latest price: $41.45. Market cap $1.94B. Trailing PE -31.64. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2026-05-01 · $34.00 2026-10-30 · $41.45 (+21.91%)

Earnings

Most Recent

Aug 11, 2026

EPS $-0.80 vs est. $-0.73

Missed by $0.07

Next Earnings

Nov 10, 2026

EPS estimate $-0.51

Proprietary Signals

Signal snapshot temporarily unavailable.

About Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-31.64×
P/S (TTM)	0.00×
P/B	2.75×
P/FCF (TTM)	-43.79×
EV / EBITDA	-34.31×
EV / Sales	0.00×
Earnings Yield	-3.75%
Free Cash Flow Yield	-2.28%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.70B
Net Income (TTM)	-$72.66M
Free Cash Flow (TTM)	-$44.22M
Net Debt	-$236.34M
Working Capital	$451.05M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-36.64%
Return on Invested Capital	-10.91%